Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    SPIC Ltd

    SPIC (EPC) offers wide range of Engineering services to clients in the field of Oil and Gas, Petrochemical and Chemical sectors. Has the capacity to do Engineering for complete

  • No Image
    Sri Krishna Pharmaceuticals Ltd

    Sri Krishna Pharmaceuticals Limited (SKPL), established in 1974, pioneering the manufacture of ACETAMINOPHEN (PARACETAMOL) for the domestic market, is today a leading supplier o

  • No Image
    Staywell Formulation Pvt Ltd

    Staywell Formulation Pvt Ltd was incorporated in the year 2009 based in New Delhi. The company's manufacturing facility is located in Roorkee, Dist. Haridwar in Uttaranchal. It